BSNL Deploys 4G Mobile Services in Delhi Under Partner Network Access Arrangement

Bionano Genomics has raised its 2025 OGM installation target to 25 as consumables and software revenue climbs 16%. CEO Robert Erik Holmlin described Q2 2025 as "solid," attributing the positive performance to a strategic shift made in September 2024 that prioritized supporting routine users of Bionano's optical genome mapping technology.

Bionano Genomics, Inc. (NASDAQ: BNGO) reported its Q2 2025 financial results on August 14, 2025, showcasing a strategic shift that is beginning to yield positive results. The company reported a net loss of $6.86 million, a 13.4% year-over-year (Y/Y) decrease in revenue to $6.73 million, which exceeded analyst estimates by $0.17 million [1]. However, the company's gross margin expanded to 52%, up from 35% in Q2 2024, indicating a significant improvement in operational efficiency [2].

The company's CEO, Robert Erik Holmlin, attributed the positive performance to a strategic shift made in September 2024 that prioritized supporting routine users of Bionano's optical genome mapping (OGM) technology. This shift has led to a 16% increase in consumables and software revenue, which now form the bulk of recurring sales [2]. The company also reported a 17% increase in flowcell sales, with 7,233 units sold in Q2 2025 compared to 6,165 in Q2 2024 [3].

Holmlin further stated that the company's strategy shift is working, with gross margin above 50% in Q2 2025. This was achieved through a combination of higher-margin consumables and software sales, as well as internal cost reductions. Operating expenses fell sharply by 42% to $11.3 million, a significant decrease from the prior year [2].

The company's installed base of OGM systems increased to 378, a 4.1% increase from the prior year, reflecting stable demand within key customer segments. The company also reported a record 119 peer-reviewed publications, highlighting the growing utilization of OGM technology in research markets [3].

Looking ahead, Bionano Genomics has raised its 2025 OGM installation target to 20–25, up from its prior guidance of 15–20. The company expects full-year 2025 revenue to be in the range of $26.0 to $30.0 million, with Q3 2025 revenue expected to be in the range of $6.7 to $7.2 million [1]. The company's cash runway is projected to extend into Q1 2026, assuming ongoing expense controls and stable market conditions [1].

References:
[1] https://seekingalpha.com/news/4485650-bionano-genomics-reports-q2-results
[2] https://www.nasdaq.com/articles/bionano-genomics-posts-q2-margin-gain
[3] https://www.biospace.com/press-releases/bionano-reports-second-quarter-2025-results-and-highlights-recent-business-progress